To evaluate the value of multiparametric MRI for determination of early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma.
A computerized search of Ovid-MEDLINE and EMBASE up to 1 October 2017 was performed to find studies on the diagnostic performance of multiparametric MRI for differentiating true progression from pseudoprogression. The beginning search date was not specified. Pooled estimates of sensitivity and specificity were obtained using hierarchical logistic regression modeling. We performed meta-regression and sensitivity analyses to explain the effects of the study heterogeneity.
Nine studies including 456 patients were included. Pooled sensitivity and specificity were 84 % (95 % CI 74–91) and 95 % (95 % CI 83–99), respectively. Area under the hierarchical summary receiver operating characteristic curve was 0.95 (95 % CI 0.92–0.96). Meta-regression showed true progression in the study population, the mean age and the reference standard were significant factors affecting heterogeneity.
Multiparametric MRI may be used as a potential surrogate endpoint for assessment of early treatment response, especially in the differentiation of true progression from pseudoprogression. However, based on the current evidence, monoparametric and multiparametric MRI perform equally in the clinical context. Further evaluation will be needed.
• Multiparametric MRI shows high diagnostic performance for early treatment response in glioblastoma.
• Multiparametric MRI could differentiate true progression from pseudoprogression in newly diagnosed glioblastoma.
• The normalized rCBV derived from DSC was the most commonly used parameter.
This is a preview of subscription content,to check access.
Access this article
Similar content being viewed by others
Apparent diffusion coefficient
Arterial spin labeling
Area under the receiver operating characteristic curve
Cerebral blood flow
Dynamic contrast-enhanced imaging
Dynamic susceptibility-weighted contrast-enhanced imaging
Diffusion tensor imaging
Hierarchical summary receiver operating characteristic
Initial area under the curve
Magnetic resonance imaging
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Quality Assessment of Diagnostic Accuracy Studies-2
Response assessment in neuro-oncology
Relative cerebral blood volume
Abbasi AW, Westerlaan HE, Holtman GA, Aden KM, van Laar PJ, van der Hoorn A (2017) Incidence of tumour progression and pseudoprogression in high-grade gliomas: a systematic review and meta-analysis. Clin Neuroradiol
Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–2197
Stuplich M, Hadizadeh DR, Kuchelmeister K et al (2012) Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide. J Clin Oncol 30:e180–e183
Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972
van Dijken BR, van Laar PJ, Holtman GA, van der Hoorn A (2017) Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis. Eur Radiol
Cha J, Kim ST, Kim HJ et al (2014) Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis. AJNR Am J Neuroradiol 35:1309–1317
Choi YJ, Kim HS, Jahng GH, Kim SJ, Suh DC (2013) Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging. Acta Radiol 54:448–454
Di Costanzo A, Scarabino T, Trojsi F et al (2014) Recurrent glioblastoma multiforme versus radiation injury: a multiparametric 3-T MR approach. Radiol Med 119:616–624
Hu X, Wong KK, Young GS, Guo L, Wong ST (2011) Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma. J Magn Reson Imaging 33:296–305
Park JE, Kim HS, Goh MJ, Kim SJ, Kim JH (2015) Pseudoprogression in patients with glioblastoma: assessment by using volume-weighted voxel-based multiparametric clustering of MR imaging data in an independent test set. Radiology 275:792–802
Prager AJ, Martinez N, Beal K, Omuro A, Zhang Z, Young RJ (2015) Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol 36:877–885
Seeger A, Braun C, Skardelly M et al (2013) Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease. Acad Radiol 20:1557–1565
Wang S, Martinez-Lage M, Sakai Y et al (2016) Differentiating tumor progression from pseudoprogression in patients with glioblastomas using diffusion tensor imaging and dynamic susceptibility contrast MRI. AJNR Am J Neuroradiol 37:28–36
Yoo RE, Choi SH, Kim TM et al (2015) Independent poor prognostic factors for true progression after radiation therapy and concomitant temozolomide in patients with glioblastoma: subependymal enhancement and low ADC value. AJNR Am J Neuroradiol 36:1846–1852
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W65–W94
Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536
Higgins J, Green S Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. http://handbook.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm. Updated March 2011. Accessed October 2nd, 2017
Deville WL, Buntinx F, Bouter LM et al (2002) Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2:9
Suh CH, Park SH (2016) Successful publication of systematic review and meta-analysis of studies evaluating diagnostic test accuracy. Korean J Radiol 17:5–6
Kim KW, Lee J, Choi SH, Huh J, Park SH (2015) Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers-part I. general guidance and tips. Korean J Radiol 16:1175–1187
Lee J, Kim KW, Choi SH, Huh J, Park SH (2015) Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers-part II. Statistical methods of meta-analysis. Korean J Radiol 16:1188–1196
Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58:882–893
Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32:1978–1985
Jensen RL (2009) Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92:317–335
Hyare H, Thust S, Rees J (2017) Advanced MRI techniques in the monitoring of treatment of gliomas. Curr Treat Options Neurol 19:11
Deeks JJ, Bossuyt PM, Gatsonis C (eds) (2013) Cochrane handbook for systematic reviews of diagnostic test accuracy version 1.0.0. The Cochrane Collaboration. http://srdta.cochrane.org/handbook-dta-reviews. Accessed 9 Oct 2017.
Trikalinos TA, Balion CM, Coleman CI et al (2012) Chapter 8: meta-analysis of test performance when there is a ‘gold standard’. J Gen Intern Med 27(Suppl 1):S56–S66
This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1720030)
The scientific guarantor of this publication is Ho Sung Kim.
Conflict of interest
The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.
Statistics and biometry
One of the authors (Chong Hyun Suh) has significant statistical expertise (4 years of experience in a systematic review and meta-analysis).
Written informed consent was not required for this study because of the nature of our study, which was a systemic review and meta-analysis.
Institutional Review Board approval was not required because of the nature of our study, which was a systemic review and meta-analysis.
• systematic review
• performed at one institution
Electronic supplementary material
About this article
Cite this article
Suh, C.H., Kim, H.S., Jung, S.C. et al. Multiparametric MRI as a potential surrogate endpoint for decision-making in early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a systematic review and meta-analysis. Eur Radiol 28, 2628–2638 (2018). https://doi.org/10.1007/s00330-017-5262-5